SavedAdd your journal

Journals / Türk Dermatoloji Dergisi / 2008 / Cilt: 2 - Sayı: 3

Our approach to toxic epidermal necrolysis and review of current treatment alternatives

Toksik epidermal nekrolize yaklaşım prensiplerimiz ve güncel tedavinin gözden geçirilmesi

Sinan ÖKSÜZ
Fatih UYGUR
Can KOPAL
Celalettin SEVER
Pages
61–64
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, current treatment practice and our treatment strategy for TEN is discussed and eight patients treated in our clinic between the years 2001 and 2008 are reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Toxic epidermal necrolysis (TEN) is a clinical entity which has a 30 to 40 % mortality rate, with necrolysis affecting the entire epidermis.
📊
Key Findings & Data:Antibiotics, nonsteroidal anti-inflammatory drugs and anticonvulsants are offender drugs in TEN etiology.
💡
Conclusion & Impact:In this study, current treatment practice and our treatment strategy for TEN is discussed and eight patients treated in our clinic between the years 2001 and 2008 are reviewed.
🔬Design:Review & Systematic Survey
📍Scope:2001 Verileri
⚙️Variables:Domain Parameters

Abstract

Toxic epidermal necrolysis (TEN) is a clinical entity which has a 30 to 40 % mortality rate, with necrolysis affecting the entire epidermis. Antibiotics, nonsteroidal anti-inflammatory drugs and anticonvulsants are offender drugs in TEN etiology. A standard treatment protocol with proven efficacy is still lacking. In this study, current treatment practice and our treatment strategy for TEN is discussed and eight patients treated in our clinic between the years 2001 and 2008 are reviewed.

Özet

Toksik epidermal nekroliz (TEN) tüm epidermisi tutan yaygın nekroliz ile karakterize % 30-40 oranlarında mortalite ile seyreden klinik bir tablodur. Etiyolojide antibiyotikler, nonsteroid anti enflamatuvar ilaçlar ve antikonvülzanlar sorumlu tutulmaktadır. Tedavide, etkinliği kanıtlanmış standart bir protokol bulunmamaktadır. Bu çalışmada, kliniğimizce 2001 - 2008 yılları arasında takip edilen sekiz TEN olgusundaki yaklaşım prensiplerimiz ve güncel tedavi uygulamaları irdelenmektedir

🔖

Cite This Article

ÖKSÜZ, S., UYGUR, F., KOPAL, C., SEVER, C. (2022). Our approach to toxic epidermal necrolysis and review of current treatment alternatives. Türk Dermatoloji Dergisi, Cilt: 2 - Sayı: 3, 61–64. https://ajindex.com/articles/621636

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005;94:419-36
  2. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981 - 1985. Arch Dermatol 1990;126:37-42
  3. Leaute - Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000;83:347-52
  4. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: Our current understanding. Allergol Int 2006;55:9-16
  5. Avakian R, Flowers FP, Araujo OE, Ramos-Caro FA. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991: 25:69-79
  6. Romero-Rangel T, Stavrou P, Cotter J, et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000;130:25-32
  7. Asz J, Asz D, Moushey R, et al. Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing. J Pediatr Surg 2006;41:9-12
  8. Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in vitro “rechalange” with hydroxylamine metabolites. Ann Intern Med 1989;110:286-289
  9. Yip LW, Thong BY, Tan AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye 2005;19:846-53
  10. Snyder RA, Elias PM. Toxic epidermal necrolysis and staphylococcal scalded skin syndrome. Dermatol Clin 1983;1:235-48
  11. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12
  12. Guibal F, Bastuji-Garin S, Chosidow O, et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995;131:669-72
  13. Furubacke A, Berlin G, Anderson C, Sjoberg F. Lack of significant treatment effect of plasma Exchange in the treatment of drug induced toxic epidermal necrolysis. Intensive Care Med 1999;25:1307-10
  14. Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated succesfully with cyclophosphamide. Br J Dermatol 1998;139:1127-8
  15. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-5
  16. Hunger RE, Hunziker T, Buettiker U. Rapid reso